stockportfolio.pro
Kailera Therapeutics, Inc. (KLRA)
Healthcare · Biotechnology · NasdaqGS
Kailera Therapeutics, Inc. revenue & earnings — last 1 fiscal years
| Metric | 2025 |
|---|---|
| Revenue | $0 |
| Gross profit | — |
| Net income | $-148.96M |
| Net margin | — |
Source: Kailera Therapeutics, Inc. SEC filings (10-K).
Explore 1 years of Kailera Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track KLRA in your portfolio →
Kailera Therapeutics, Inc. financial history by metric
About Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Kailera Therapeutics, Inc. — frequently asked questions
What is Kailera Therapeutics, Inc.'s revenue?
Kailera Therapeutics, Inc. (KLRA) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Kailera Therapeutics, Inc. profitable?
No — KLRA reported a net loss of $-148.96M in fiscal 2025.
What is KLRA's P/E ratio?
Kailera Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Kailera Therapeutics, Inc. have?
As of fiscal year 2025, KLRA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Kailera Therapeutics, Inc.'s market cap?
Kailera Therapeutics, Inc. (KLRA) has a market capitalization of about $2.56B, based on the latest data in our nightly-refreshed cache.
When does Kailera Therapeutics, Inc.'s fiscal year end?
KLRA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Kailera Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 1 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.